biote Corp. (NASDAQ:BTMD - Get Free Report) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 806,900 shares, a decline of 8.5% from the October 15th total of 881,500 shares. Based on an average daily volume of 155,700 shares, the short-interest ratio is presently 5.2 days. Currently, 2.7% of the shares of the company are sold short.
Institutional Trading of biote
A number of hedge funds have recently made changes to their positions in BTMD. Barclays PLC raised its stake in biote by 52.3% in the 3rd quarter. Barclays PLC now owns 77,196 shares of the company's stock valued at $432,000 after acquiring an additional 26,510 shares during the period. K2 Principal Fund L.P. bought a new position in shares of biote in the third quarter valued at about $277,000. Jane Street Group LLC raised its position in shares of biote by 24.7% in the third quarter. Jane Street Group LLC now owns 16,873 shares of the company's stock valued at $94,000 after purchasing an additional 3,342 shares during the period. Wellington Management Group LLP bought a new stake in shares of biote during the 3rd quarter worth about $295,000. Finally, State Street Corp grew its stake in biote by 13.7% in the 3rd quarter. State Street Corp now owns 475,491 shares of the company's stock valued at $2,653,000 after buying an additional 57,290 shares during the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.
biote Stock Down 18.0 %
Shares of BTMD stock traded down $1.18 on Friday, reaching $5.39. The stock had a trading volume of 484,535 shares, compared to its average volume of 129,898. biote has a 12 month low of $3.65 and a 12 month high of $8.44. The firm has a market capitalization of $292.25 million, a price-to-earnings ratio of 20.73 and a beta of 0.94. The firm's 50-day moving average is $5.52 and its two-hundred day moving average is $6.28.
biote Company Profile
(
Get Free Report)
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider biote, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and biote wasn't on the list.
While biote currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
